Product Images Clopidogrel Bisulfate

This text appears to be a label for a prescription medication. The medication is in tablet form with a strength of 75 mg, and there are 90 tablets in the bottle. The label includes important information such as the NDC number, expiration date, lot number, manufacturing details, and instructions for storage. It also states the medication should be kept out of reach of children and provides contact information for the repackaging company.*

This is a description of Clopidogrel 75 mg tablets, with a quantity of 30 tablets per package. The medication is prescription-only and the NDC number is 70518-0717-00. It is manufactured by Dr. Reddy's in Shreveport, LA. The medication should be kept out of reach of children. The storage instructions are to keep it at 20-25°C (58-77°F), with permissible excursions to 15-30°C (59-86°F). Directions for use are indicated in the package insert. The repackaging was done by RemedyRepack Inc. based in Indiana, PA.*

This appears to be a comparison of the effect of co-administered Proton Pump Inhibitors (PPIs) on the area under the curve (AUC) of an active metabolite. The given values may represent mean and 90% confidence intervals for Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole at different doses. More specific details or interpretations would require additional context or information.*

This text provides data on the use of Clopidogrel and aspirin (plus other standard therapies as appropriate) in reducing cumulative event rates over a period of 34 to 85 months of follow-up. The cumulative event rate is reported to be 0.00009.*

This text provides statistical data comparing deaths between a placebo and clopidogrel group, showing a 7% proportional risk reduction associated with clopidogrel (p=0.03) within 28 days since randomization.*

This text provides information on a clinical study comparing the outcomes of patients treated with Placobo (placebo) versus Clopidogrel. It shows the number of patients experiencing events such as death, reinfarction, or stroke before discharge, with the respective percentages. Additionally, it highlights a 9% proportional risk reduction associated with Clopidogrel compared to Placobo, with a p-value of 0.002. The data is presented in relation to the days since randomization, up to 28 days.*